Hussman Strategic Advisors Inc. Takes $1.44 Million Position in ResMed Inc. (NYSE:RMD)

Hussman Strategic Advisors Inc. purchased a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 6,300 shares of the medical equipment provider's stock, valued at approximately $1,441,000.

A number of other institutional investors also recently bought and sold shares of the stock. True Wealth Design LLC raised its stake in shares of ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 110 shares during the period. Ashton Thomas Securities LLC bought a new position in ResMed during the 3rd quarter valued at about $34,000. Rosenberg Matthew Hamilton bought a new position in ResMed during the 4th quarter valued at about $54,000. Capital Performance Advisors LLP purchased a new stake in ResMed in the 3rd quarter worth about $60,000. Finally, Venturi Wealth Management LLC boosted its position in shares of ResMed by 55.7% during the third quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 122 shares during the period. 54.98% of the stock is currently owned by institutional investors.

Insider Activity at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total transaction of $491,300.00. Following the sale, the director now directly owns 81,218 shares of the company's stock, valued at approximately $19,951,201.70. This trade represents a 2.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the transaction, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,147 shares of company stock valued at $2,905,745 in the last ninety days. Company insiders own 0.71% of the company's stock.

ResMed Stock Down 0.5 %

NYSE RMD traded down $1.18 during trading on Friday, hitting $231.61. The company's stock had a trading volume of 518,460 shares, compared to its average volume of 955,284. ResMed Inc. has a fifty-two week low of $170.56 and a fifty-two week high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The company has a market cap of $34.02 billion, a PE ratio of 27.34, a P/E/G ratio of 1.55 and a beta of 0.70. The business's 50 day simple moving average is $237.57 and its 200-day simple moving average is $238.96.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, equities analysts anticipate that ResMed Inc. will post 9.44 EPS for the current fiscal year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. KeyCorp increased their price target on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. JPMorgan Chase & Co. raised their price target on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Robert W. Baird upped their target price on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. The Goldman Sachs Group assumed coverage on shares of ResMed in a research report on Thursday, January 16th. They set a "buy" rating on the stock. Finally, Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $244.73.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.